

Teresa PaÃ- no

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2491191/publications.pdf>

Version: 2024-02-01

8
papers

163
citations

1306789

7
h-index

1719596

7
g-index

8
all docs

8
docs citations

8
times ranked

412
citing authors

#	ARTICLE	IF	CITATIONS
1	The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care. <i>Clinical Cancer Research</i> , 2017, 23, 225-238.	3.2	42
2	Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma. <i>Haematologica</i> , 2020, 105, e116-e120.	1.7	38
3	Biological Background of Resistance to Current Standards of Care in Multiple Myeloma. <i>Cells</i> , 2019, 8, 1432.	1.8	24
4	Immune System Alterations in Multiple Myeloma: Molecular Mechanisms and Therapeutic Strategies to Reverse Immunosuppression. <i>Cancers</i> , 2021, 13, 1353.	1.7	22
5	The kinesin spindle protein inhibitor filanesib enhances the activity of pomalidomide and dexamethasone in multiple myeloma. <i>Haematologica</i> , 2017, 102, 2113-2124.	1.7	19
6	Protein Translation Inhibition is Involved in the Activity of the Pan-PIM Kinase Inhibitor PIM447 in Combination with Pomalidomide-Dexamethasone in Multiple Myeloma. <i>Cancers</i> , 2020, 12, 2743.	1.7	9
7	Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial. <i>Cancers</i> , 2020, 12, 3615.	1.7	7
8	Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma. <i>Cells</i> , 2021, 10, 559.	1.8	2